

Supplementary Table S1. Significantly mutated genes in renal cell carcinoma identified by The Cancer Genome Atlas.

Histology	Significantly Mutated Genes (SMGs)
Clear cell RCC	<i>VHL, PBRM1, SETD2, KDM5C, PTEN, BAP1, MTOR, TP53, PIK3CA, MSRI, TXNIP, TCEB1, NFE2L2, BTNL3, SLITRK6, RHEB, ARID1A, NPNT, CCNB</i>
Papillary RCC	<i>MET, SETD2, NF2, KDM6A, SMARCB1, FAT1, BAP1, PBRM1, STAG2, NFE2L2, TP53, FH, NF2</i>
Chromophobe RCC	<i>TP53, PTEN, TERT, KIT</i>
Oncocytoma	<i>CCND1</i>

Supplementary Table S2. Somatic mutation rates in clear cell RCC specimens stratified by presence of ACKD.

Mutated Gene	No ACKD <i>n</i> (%)	ACKD <i>n</i> (%)	Total <i>n</i> (%)	p value
Total	156 (81.7)	35 (18.3)	191	
<i>VHL</i>	82 (52.6)	16 (45.7)	98 (51.3)	0.575
<i>PBRM1</i>	65 (41.7)	12 (34.3)	77 (40.3)	0.452
<i>SETD2</i>	41 (26.3)	6 (17.1)	47 (24.6)	0.287
<i>KDM5C</i>	15 (9.6)	2 (5.7)	17 (8.9)	0.743
<i>PTEN</i>	7 (4.5)	1 (2.9)	8 (4.2)	1.000
<i>BAP1</i>	20 (12.8)	1 (2.9)	21 (11.0)	0.132
<i>MTOR</i>	18 (11.5)	4 (11.4)	22 (11.5)	1.000
<i>TP53</i>	4 (2.6)	3 (8.6)	7 (3.7)	0.117
<i>PIK3CA</i>	11 (7.1)	1 (2.9)	12 (6.3)	0.699
<i>MSRI</i>	1 (0.6)	0 (0.0)	1 (0.5)	1.000
<i>TXNIP</i>	4 (2.6)	0 (0.0)	4 (2.1)	1.000
<i>ELOC</i>	3 (1.9)	1 (2.9)	4 (2.1)	0.558
<i>NFE2L2</i>	8 (5.1)	0 (0.0)	8 (4.2)	0.355
<i>BTNL3</i>	1 (0.6)	0 (0.0)	1 (0.5)	1.000
<i>SLITRK6</i>	2 (1.3)	0 (0.0)	2 (1.0)	1.000
<i>RHEB</i>	2 (1.3)	1 (2.9)	2 (1.0)	0.457
<i>ARID1A</i>	13 (8.3)	5 (14.3)	18 (9.4)	0.333
<i>NPNT</i>	4 (2.6)	1 (2.9)	5 (2.6)	1.000
<i>CCNB1</i>	0 (0.0)	1 (2.9)	1 (0.5)	0.183
<i>MET</i>	1 (0.6)	1 (2.9)	2 (1.0)	0.334
<i>NF2</i>	3 (1.9)	0 (0.0)	3 (1.6)	1.000
<i>KDM6A</i>	5 (3.2)	0 (0.0)	5 (2.6)	0.587
<i>SMARCB1</i>	1 (0.6)	1 (2.9)	2 (1.0)	0.334
<i>FAT1</i>	11 (7.1)	3 (8.6)	14 (7.3)	0.724

<i>STAG2</i>	4 (2.6)	1 (2.9)	5 (2.6)	1.000
<i>FH</i>	1 (0.6)	0 (0.0)	1 (0.5)	1.000
<i>TERT</i>	1 (0.6)	0 (0.0)	1 (0.5)	1.000
<i>KIT</i>	1 (0.6)	1 (2.9)	2 (1.0)	0.334
<i>CCND1</i>	0 (0.0)	0 (0.0)	0 (0.0)	1.000

Supplementary Table S3. Univariable and multivariable analysis of *VHL* somatic mutational status in RCC specimens.

		No	Yes	OR (univariable)	OR (multivariable)
AKD	No	131 (55.7)	104 (44.3)	-	-
	Yes	39 (63.9)	22 (36.1)	0.71 (0.39-1.26, p=0.250)	0.76 (0.41-1.39, p=0.371)
Age at Diagnosis	Mean (SD)	60.2 (12.2)	60.2 (11.2)	1.00 (0.98-1.02, p=0.975)	-
Sex	Female	59 (56.2)	46 (43.8)	-	-
	Male	111 (58.1)	80 (41.9)	0.92 (0.57-1.50, p=0.749)	-
Histology	Clear Cell	93 (48.7)	98 (51.3)	-	-
	Papillary	27 (84.4)	5 (15.6)	0.18 (0.06-0.44, p=0.001)	0.18 (0.06-0.46, p=0.001)
	Chromophobe	20 (100.0)	0 (0.0)	-	-
	NOS	30 (56.6)	23 (43.4)	0.73 (0.39-1.34, p=0.309)	0.74 (0.40-1.36, p=0.327)
Stage	I	84 (61.8)	52 (38.2)	-	-
	II	14 (45.2)	17 (54.8)	1.96 (0.89-4.37, p=0.094)	-
	III	57 (57.0)	43 (43.0)	1.22 (0.72-2.06, p=0.461)	-
	IV	15 (51.7)	14 (48.3)	1.51 (0.67-3.39, p=0.318)	-